TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 16502725

Group type: EXPERIMENTAL
Intervention: OKM/A group: omeprazole 20 mg twice a day, clarithromycin 500 mg twice a day, metronidazole 500 mg or amoxicillin 1000 mg twice a day
Number of subjects: 65

Group type: COMPARATOR
Intervention: OBTM group: omeprazole 20 mg twice a day, colloid bismuth subcitrate (de-nol) 120 mg four times a day, tetracycline 500 mg four times a day, metronidazole 500 mg twice or 250 mg four times a day
Number of subjects: 65
Study: 12030739

Group type: EXPERIMENTAL
Intervention: Noninvasive positive pressure ventilation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 10346552

Group type: EXPERIMENTAL
Intervention: Short revisit intervals (1 to 2 months)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Long revisit intervals (4 to 8 months)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Appointment made immediately after the initial visit
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Calling back for an appointment according to the interval recommended by the provider
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Increased number of clinic sessions for providers
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Reduced number of clinic sessions for providers
Number of subjects: 0
Study: 8748321

Group type: EXPERIMENTAL
Intervention: Mannitol (2.264 g)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Mannitol solution
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Mannitol tablet
Number of subjects: 7

Group type: COMPARATOR
Intervention: Sucrose (control)
Number of subjects: 7
Study: 1683334

Group type: EXPERIMENTAL
Intervention: Zotepine
Number of subjects: 40

Group type: COMPARATOR
Intervention: Perazine
Number of subjects: 40
Study: 6754511

Group type: EXPERIMENTAL
Intervention: Alclometasone dipropionate ointment (0.05%) applied twice daily for 3 weeks
Number of subjects: 66

Group type: COMPARATOR
Intervention: Desonide ointment (0.05%) applied twice daily for 3 weeks
Number of subjects: 66
Study: 31350585

Group type: EXPERIMENTAL
Intervention: CTO-PCI
Number of subjects: 200

Group type: COMPARATOR
Intervention: No-CTO PCI
Number of subjects: 200
Study: 31345563

Group type: EXPERIMENTAL
Intervention: Surgical treatment for distal radius fracture
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Participants with severe pain and high school education or less
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Participants with less pain, more education, age 87 years or younger, and one or no comorbid conditions
Number of subjects: 0

Group type: COMPARATOR
Intervention: Treatment type or radiographic measurements
Number of subjects: 0
Study: 28406129

Group type: EXPERIMENTAL
Intervention: Warm saline rinse (gargled twice daily)
Number of subjects: 100
Study: 26691278

Group type: EXPERIMENTAL
Intervention: Ivermectin 1% cream QD
Number of subjects: 764

Group type: COMPARATOR
Intervention: Metronidazole 0.75% cream BID
Number of subjects: 764
Study: 24429255

Group type: EXPERIMENTAL
Intervention: 10% hydrogen peroxide whitening strips
Number of subjects: 170

Group type: COMPARATOR
Intervention: Placebo strips without peroxide
Number of subjects: 170
Study: 22253269

Group type: EXPERIMENTAL
Intervention: Neutral Position (0 degrees)
Number of subjects: 1320

Group type: COMPARATOR
Intervention: Head Turned (45 degrees)
Number of subjects: 1320

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 1320
Study: 19648304

Group type: EXPERIMENTAL
Intervention: Sonographic image-guided injection
Number of subjects: 148

Group type: COMPARATOR
Intervention: Conventional palpation-guided injection
Number of subjects: 148
Study: 17309916

Group type: EXPERIMENTAL
Intervention: 0.9% saline infusion plus NAC (n=111)
Number of subjects: 326

Group type: EXPERIMENTAL
Intervention: sodium bicarbonate infusion plus NAC (n=108)
Number of subjects: 326

Group type: EXPERIMENTAL
Intervention: 0.9% saline plus ascorbic acid plus NAC (n=107)
Number of subjects: 326
Study: 15381546

Group type: EXPERIMENTAL
Intervention: Focal CO(2) laser resurfacing of photodamaged forearms
Number of subjects: 11
Study: 12360766

Group type: EXPERIMENTAL
Intervention: Lavender essential oil
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Chamomile essential oil
Number of subjects: 5
Study: 9843256

Group type: EXPERIMENTAL
Intervention: Topical amethocaine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sub-conjunctival bupivacaine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Topical normal saline (placebo)
Number of subjects: 0
Study: 7814312

Group type: EXPERIMENTAL
Intervention: Facilitated communication
Number of subjects: 7
Study: 2569995

Group type: EXPERIMENTAL
Intervention: Acrivastine 8 mg
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Acrivastine 4 mg
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Terfenadine 60 mg
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: All active treatments (Acrivastine and Terfenadine)
Number of subjects: 56
Study: 22339

Group type: EXPERIMENTAL
Intervention: Lorazepam
Number of subjects: 84

Group type: COMPARATOR
Intervention: Diazepam
Number of subjects: 84
Study: 31758541

Group type: EXPERIMENTAL
Intervention: Follitropin alfa 'conventional' dosing arm of the ESTHER‐1 trial
Number of subjects: 0

Group type: COMPARATOR
Intervention: Clinic subpopulation using controlled ovarian stimulation with FSH
Number of subjects: 0
Study: 30654990

Group type: EXPERIMENTAL
Intervention: Open-label placebo with rationale (OPR+)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Open-label placebo without rationale (OPR-)
Number of subjects: 160

Group type: COMPARATOR
Intervention: No treatment (NT)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Deceptive placebo (DP)
Number of subjects: 160
Study: 28288299

Group type: EXPERIMENTAL
Intervention: Positive dental images
Number of subjects: 60

Group type: COMPARATOR
Intervention: Neutral cartoon images
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 60
Study: 25611762

Group type: EXPERIMENTAL
Intervention: Voice therapy enhanced by MP4 support (4 sessions)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Voice therapy without MP4 support (4 sessions)
Number of subjects: 40
Study: 24047450

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral side-effect prevention training (SEPT)
Number of subjects: 184

Group type: COMPARATOR
Intervention: Standard medical care
Number of subjects: 184

Group type: COMPARATOR
Intervention: Manualized supportive therapy
Number of subjects: 184
Study: 21651853

Group type: EXPERIMENTAL
Intervention: Achn inhibition group (transfected with psi‐Achn)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Achn induction group (transfected with pcDNA‐Achn)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cotransfection group (cotransfected with psi‐CASK and pcDNA‐Achn)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Achn transfection group (transfected with pcDNA‐Achn)
Number of subjects: 0
Study: 19761535

Group type: EXPERIMENTAL
Intervention: Intravenous supplementation of trace elements (Se, Mn, Zn)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 17668563

Group type: EXPERIMENTAL
Intervention: HAART plus cotrimoxazole
Number of subjects: 581

Group type: COMPARATOR
Intervention: Cotrimoxazole alone
Number of subjects: 581
Study: 15819377

Group type: EXPERIMENTAL
Intervention: Lifestyle interventions (dietary changes, physical exercise, weight control)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Drug treatments (glycaemia treatment, lipidaemia treatment, blood pressure lowering, platelet aggregation inhibitors)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Multifactorial treatment (open randomised trial)
Number of subjects: 100
Study: 11487422

Group type: EXPERIMENTAL
Intervention: Cue Exposure Treatment (CET)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Coping Skills Training (CST)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: CET
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: CET and CST
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: CST
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Urge-specific strategies taught in CET
Number of subjects: 100

Group type: COMPARATOR
Intervention: Meditation-relaxation control
Number of subjects: 100

Group type: COMPARATOR
Intervention: Education control
Number of subjects: 100
Study: 9571355

Group type: EXPERIMENTAL
Intervention: Perindopril (4-8 mg daily)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Carvedilol (25-50 mg daily)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control group (20 nondiabetic nonhypertensive subjects)
Number of subjects: 26
Study: 7829413

Group type: EXPERIMENTAL
Intervention: Cefoperazone-sulbactam
Number of subjects: 76

Group type: COMPARATOR
Intervention: Clindamycin plus gentamicin
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Cefoperazone
Number of subjects: 76

Group type: COMPARATOR
Intervention: Clindamycin
Number of subjects: 76
Study: 2905151

Group type: EXPERIMENTAL
Intervention: Ebastine 10 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ebastine 50 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31478415

Group type: EXPERIMENTAL
Intervention: GM‐CSF supplementation (0.6 ng/mL)
Number of subjects: 631

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 631
Study: 29408333

Group type: EXPERIMENTAL
Intervention: Tetravalent dengue vaccine
Number of subjects: 22603

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22603
Study: 27382685

Group type: COMPARATOR
Intervention: Manipulative reduction
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: TRV-CRP
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Both methods
Number of subjects: 132
Study: 25245814

Group type: EXPERIMENTAL
Intervention: Baclofen (GABABR agonist)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Diazepam (positive modulator at GABAARs)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 21254867

Group type: EXPERIMENTAL
Intervention: 1% clindamycin phosphate gel applied twice daily and 0.1% adapalene gel applied once daily for 4 weeks (initial treatment) followed by either OD group (adapalene applied once daily) or TW group (adapalene applied once daily on 2 days per week) for 4 weeks (maintenance phase)
Number of subjects: 66
Study: 20368559

Group type: EXPERIMENTAL
Intervention: Capecitabine (given in two divided daily doses for 14 consecutive days of a 21-day cycle for six cycles)
Number of subjects: 161

Group type: COMPARATOR
Intervention: Standard chemotherapy
Number of subjects: 161
Study: 18395398

Group type: EXPERIMENTAL
Intervention: High potency opioids prescribed by primary oncology team
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Pain Management Index scores
Number of subjects: 131
Study: 15974840

Group type: EXPERIMENTAL
Intervention: Autogenous connective tissue (CT) graft beneath a coronally advanced flap
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Acellular dermal matrix (ADM) graft beneath a coronally advanced flap
Number of subjects: 4

Group type: COMPARATOR
Intervention: Coronally advanced flap alone
Number of subjects: 4
Study: 12867403

Group type: EXPERIMENTAL
Intervention: Lidocaine 2% gel
Number of subjects: 14

Group type: COMPARATOR
Intervention: Amethocaine 1% eyedrops
Number of subjects: 14
Study: 11284783

Group type: EXPERIMENTAL
Intervention: Nabumetone 1 g b.d. by mouth for 2 weeks
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Aspirin 325 mg daily for 2 weeks
Number of subjects: 180

Group type: COMPARATOR
Intervention: Control group (no aspirin or NSAIDs for 2 weeks)
Number of subjects: 180
Study: 9261860

Group type: EXPERIMENTAL
Intervention: 100 mg KDI-792
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: 200 mg KDI-792
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 8501488

Group type: EXPERIMENTAL
Intervention: LSA2L2
Number of subjects: 429

Group type: COMPARATOR
Intervention: COMP
Number of subjects: 429
Study: 3030087

Group type: EXPERIMENTAL
Intervention: Enalapril (20 mg/day, range 10 to 40)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Bendrofluazide (5 mg/day, range 2.5 to 10)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 40

Group type: COMPARATOR
Intervention: Bendrofluazide
Number of subjects: 40
Study: 29984336

Group type: EXPERIMENTAL
Intervention: Plasma-kinetic (PK) system
Number of subjects: 121

Group type: COMPARATOR
Intervention: Monopolar system
Number of subjects: 121
Study: 27659568

Group type: EXPERIMENTAL
Intervention: Polymer-coated guidewires
Number of subjects: 235

Group type: COMPARATOR
Intervention: Non-polymer-coated guidewires
Number of subjects: 235
Study: 25623409

Group type: EXPERIMENTAL
Intervention: Naltrexone with combined behavioral intervention (CBI)
Number of subjects: 1197

Group type: COMPARATOR
Intervention: Naltrexone without CBI
Number of subjects: 1197
Study: 23080269

Group type: EXPERIMENTAL
Intervention: 5% povidone-iodine (Group A)
Number of subjects: 73

Group type: COMPARATOR
Intervention: 0.02% chlorhexidine with eyelid eversion (Group B)
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: 0.02% chlorhexidine without eyelid eversion (Group C)
Number of subjects: 73
Study: 20622370

Group type: EXPERIMENTAL
Intervention: High-dose-rate intracavitary radiotherapy (HDR-ICRT) with ovoid separation categorized into < 25 mm
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: High-dose-rate intracavitary radiotherapy (HDR-ICRT) with ovoid separation categorized into > 36 mm
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: High-dose-rate intracavitary radiotherapy (HDR-ICRT) with ovoid separation categorized into 26-35 mm
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: High-dose-rate intracavitary radiotherapy (HDR-ICRT)
Number of subjects: 6
Study: 19027431

Group type: EXPERIMENTAL
Intervention: Internet-based self-help cognitive-behavioral therapy (CBT)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Group-based cognitive-behavioral therapy (CBT)
Number of subjects: 51
Study: 16797800

Group type: EXPERIMENTAL
Intervention: Solution of active pharmaceutical ingredient (API)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Capsule formulation
Number of subjects: 0
Study: 14624167

Group type: EXPERIMENTAL
Intervention: Ambulatory blood pressure measurement (ABPM) on the night of measurement
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control night (no ABPM)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Ambulatory blood pressure measurement (ABPM)
Number of subjects: 12
Study: 10922451

Group type: EXPERIMENTAL
Intervention: 100 J
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 200 J
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 360 J
Number of subjects: 100
Study: 8931218

Group type: EXPERIMENTAL
Intervention: Laparoscopic-assisted colectomy with limited lymph node dissection (R1+, R2)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Laparoscopic-assisted colectomy with extensive lymph node dissection (R3)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Laparoscopic-assisted colectomy
Number of subjects: 20
Study: 31080627

Group type: EXPERIMENTAL
Intervention: Family Spirit Nurture intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 0
Study: 28931531

Group type: EXPERIMENTAL
Intervention: SMC+LP
Number of subjects: 100

Group type: COMPARATOR
Intervention: SMC
Number of subjects: 100
Study: 27578808

Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stent (SES)
Number of subjects: 1012

Group type: COMPARATOR
Intervention: Paclitaxel-eluting stent (PES)
Number of subjects: 1012
Study: 25046061

Group type: EXPERIMENTAL
Intervention: Home-based intervention to improve antiretroviral adherence
Number of subjects: 110

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 110
Study: 22659666

Group type: EXPERIMENTAL
Intervention: Endoscopic variceal ligation (EVL)
Number of subjects: 168

Group type: COMPARATOR
Intervention: Propranolol
Number of subjects: 168
Study: 18841747

Group type: EXPERIMENTAL
Intervention: Test group (suture only on the attached gum)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (complete suture on free and attached gums)
Number of subjects: 20
Study: 16527711

Group type: EXPERIMENTAL
Intervention: Mirrored training boxes (experimental cohort)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Video‐endoscopic laboratory (control cohort)
Number of subjects: 26
Study: 12560300

Group type: EXPERIMENTAL
Intervention: Atracurium (0.5 mg x kg(‐1)) with propofol (2.5 mg x kg(‐1))
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Atracurium (0.5 mg x kg(‐1)) with propofol (2.0 mg x kg(‐1))
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Atracurium (0.5 mg x kg(‐1)) with propofol (1.5 mg x kg(‐1))
Number of subjects: 160

Group type: COMPARATOR
Intervention: Propofol (2.5 mg x kg(‐1)) without atracurium
Number of subjects: 160
Study: 11164075

Group type: COMPARATOR
Intervention: Pharmacia‐Upjohn 15‐mg, 16‐h patch
Number of subjects: 25

Group type: COMPARATOR
Intervention: Novartis 21‐mg, 24‐h patch
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Alza 21‐mg, 24‐h patch
Number of subjects: 25
Study: 9302344

Group type: EXPERIMENTAL
Intervention: Spironolactone (50‐100 mg/day)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study: 8362641

Group type: EXPERIMENTAL
Intervention: Modified grid laser photocoagulation
Number of subjects: 42

Group type: COMPARATOR
Intervention: Natural course of the disease (Control)
Number of subjects: 42
Study: 3098118

Group type: EXPERIMENTAL
Intervention: Clonidine
Number of subjects: 24

Group type: COMPARATOR
Intervention: Lithium
Number of subjects: 24
Study: 29655829

Group type: EXPERIMENTAL
Intervention: Sacubitril/valsartan
Number of subjects: 8399

Group type: COMPARATOR
Intervention: Enalapril
Number of subjects: 8399
Study: 27080767

Group type: EXPERIMENTAL
Intervention: lamivudine 100 mg/day
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: entecavir 0.5 mg/day
Number of subjects: 200

Group type: COMPARATOR
Intervention: standard of care (no anti-viral therapy)
Number of subjects: 200
Study: 24755993

Group type: EXPERIMENTAL
Intervention: Mindfulness-based cognitive therapy (MBCT)
Number of subjects: 126

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 126
Study: 22423353

Group type: EXPERIMENTAL
Intervention: Attention Bias Modification (ABM)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo attention training (identical stimuli to ABM)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo attention training (neutral stimuli)
Number of subjects: 40
Study: 20720257

Group type: EXPERIMENTAL
Intervention: Lysine supplementation (1 g lysine/d)
Number of subjects: 271
Study: 18519919

Group type: EXPERIMENTAL
Intervention: BAY 63‐2521 (0.25‐5 mg)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: BAY 63‐2521 (1 mg)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: BAY 63‐2521 (5 mg)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: BAY 63‐2521
Number of subjects: 58
Study: 16154547

Group type: EXPERIMENTAL
Intervention: Antidepressant naive (AN) MDD subjects
Number of subjects: 71

Group type: COMPARATOR
Intervention: Controls
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Subjects with antidepressant exposure (AE)
Number of subjects: 71
Study: 12854277

Group type: EXPERIMENTAL
Intervention: Semont's maneuver
Number of subjects: 40

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 40
Study: 10740941

Group type: EXPERIMENTAL
Intervention: Alcohol expectancy priming
Number of subjects: 0

Group type: COMPARATOR
Intervention: Positive mood induction (using positive music)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Neutral mood induction (using neutral music)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Neutral words (memory priming)
Number of subjects: 0
Study: 8609836

Group type: EXPERIMENTAL
Intervention: Dexamethasone (4 mg/d for 5 days)
Number of subjects: 0
Study: 1576049

Group type: EXPERIMENTAL
Intervention: PGI2 5 ng kg‐1 min‐1 for 6 h daily, 5 days a week for 5 weeks
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: PGI2 5 ng kg‐1 min‐1 for 6 h daily, 5 days a week for 5 weeks + molsidomine 12 mg daily
Number of subjects: 36

Group type: COMPARATOR
Intervention: Molsidomine 12 mg daily
Number of subjects: 36
Study: 3903336

Group type: EXPERIMENTAL
Intervention: Iodide treatment (200 micrograms/day orally)
Number of subjects: 155

Group type: COMPARATOR
Intervention: Control group (no iodide treatment)
Number of subjects: 155
Study: 29273913

Group type: EXPERIMENTAL
Intervention: Working memory training program
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 14
Study: 27350113

Group type: EXPERIMENTAL
Intervention: Chlorhexidine gluconate (CHG) disinfection devices installed on ships
Number of subjects: 347
Study: 25623291

Group type: EXPERIMENTAL
Intervention: Vitamin D3 (2000 IU/d)
Number of subjects: 25875

Group type: EXPERIMENTAL
Intervention: Omega-3 FA (1g/d)
Number of subjects: 25875

Group type: EXPERIMENTAL
Intervention: Vitamin D3 (2000 IU/d) and Omega-3 FA (1g/d)
Number of subjects: 25875

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25875
Study: 23352800

Group type: EXPERIMENTAL
Intervention: NETA/EE-24
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: NETA/EE-21
Number of subjects: 32
Study: 21918216

Group type: EXPERIMENTAL
Intervention: Calcium intake of 756 mg Ca/d
Number of subjects: 42

Group type: COMPARATOR
Intervention: Additional 650 mg Ca/d from dairy or calcium carbonate supplements
Number of subjects: 42
Study: 17548211

Group type: EXPERIMENTAL
Intervention: Laterality effect observed in the processing of automatic numerical information
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control for numerical distance effect
Number of subjects: 0
Study: 16971638

Group type: EXPERIMENTAL
Intervention: 3T MR imaging
Number of subjects: 40

Group type: COMPARATOR
Intervention: 1.5T MR imaging
Number of subjects: 40
Study: 12895159

Group type: EXPERIMENTAL
Intervention: Experimental group (doctors involved in drafting and implementing CPGs)
Number of subjects: 723

Group type: COMPARATOR
Intervention: Control group (doctors not involved in drafting and implementing CPGs)
Number of subjects: 723
Study: 10704711

Group type: EXPERIMENTAL
Intervention: Paclitaxel/ifosfamide
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vinorelbine/ifosfamide
Number of subjects: 0
Study: 9093724

Group type: EXPERIMENTAL
Intervention: FEC 100 (epirubicin 100 mg/m2)
Number of subjects: 456

Group type: COMPARATOR
Intervention: FEC 50 (epirubicin 50 mg/m2)
Number of subjects: 456